Tempus AI shares fall nearly 8% as investors react to Merck collaboration and Q3 earnings news

Traders Union
All News
Stocks
Tempus AI slides 7.76% today

Highlights

Tempus AI will release third quarter 2026 results on November 2, with earnings call led by CEO Eric Lefkofsky and CFO Jim Rogers.
The company extended its multi-year collaboration with Merck on intismeran autogene cancer therapy and next-generation sequencing pending regulatory approval.
Shares of Tempus AI fell 7.76% to $65.61 with notable short-term selling pressure, trading above long-term support but below key resistance, and expected to range from $61.01 to $70.22.

Expanded Merck partnership and earnings date fail to counter selling trend

Tempus AI reported that its third quarter 2026 financial results will be released on November 2, 2026, with CEO Eric Lefkofsky and CFO Jim Rogers leading the earnings call. The company has expanded a multi-year collaboration with Merck focused on the commercialization of intismeran autogene (V940/mRNA-4157) targeted at cancer therapy, as well as providing next-generation sequencing services pending regulatory approval. These developments were announced as Tempus AI continues to build one of the largest multimodal data libraries in healthcare, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees strong selling pressure and caution dominating Tempus AI despite major news releases. He notes that the inability to reclaim short- and medium-term moving averages undermines bullish attempts for now. Momentum signals remain mixed, with several oversold indicators failing to attract new buyers. Even a positive long-term structure is being tested as short-term technical levels are challenged. "A decisive break below $61.01 would expose significant downside, so I do not see an attractive risk-reward here yet," Kharitonov warns.

Viktoras Karapetjanc, expert at Traders Union, points out the robust long-term bullish structure in Tempus AI’s chart. He highlights the expanded Merck partnership and regulatory ambitions as clear growth drivers. Market absorption of short-term selling has not disrupted the company’s leadership in data-driven healthcare. "With such a solid foundation and major collaborations, I expect Tempus AI will reclaim momentum soon and offer further upside opportunities," Karapetjanc predicts.

Sholanke Dele, market strategist, remains wary as investor sentiment turns sharply negative for Tempus AI on recent news. He sees the intraday price action as a clear sign that confidence is lacking despite the company’s strategic announcements. The stock is exposed to further volatility if key supports fail. "Current momentum looks unsustainable, and downside risks remain front and center until buying conviction returns," Dele states.

Oversold momentum signals persist as price hovers near support zones

Tempus AI is trading below its 20-day moving average at $76.07 and its 50-day moving average at $67.44, but remains above the 200-day moving average at $56.76. This setup points to a strong long-term bullish structure, but clear short- and medium-term pressure from sellers. The nearest resistance stands at $65.8 (today’s low), with support at $63.6 (the week’s low). Momentum signals are mixed: MACD remains neutral, while ADX signals a buy trend. The RSI, Stochastic RSI, and CCI all indicate oversold conditions. Bull/Bear Power at 0.66 shows buyers still have some influence intraday even as the overall forecast is 'Overbought'. The Awesome Oscillator is neutral and does not confirm the dominant direction. The day’s trading saw significant selling pressure, with volatility at 10.18% and the stock closing near session lows.

Earlier, analysts noted that consumer spending trends in Malaysia were becoming increasingly price-sensitive, with households favoring discounts and smaller purchase sizes even amid ongoing economic growth. Against this backdrop, Tempus AI's ongoing volatility and near-term downside risk highlight the importance of closely monitoring the $65.8 resistance and $61.01 support levels for actionable trading opportunities.

Source of Data: TEM Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.